Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PLT 011

Next Previous
Drug Profile

PLT 011

Alternative Names: Anti-PDL1/IL10 fusion protein - Pilatus Biosciences; PLT-011

Latest Information Update: 28 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pilatus Biosciences
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; B7-H1 antigen inhibitors; Interleukin 10 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 May 2026 No recent reports of development identified for preclinical development in Cancer in Switzerland
  • 06 Nov 2025 PLT 011 is available for licensing as of 06 Nov 2025. https://www.pilatusbio.com/business-development
  • 08 Apr 2022 Pharmacodynamics data from a preclinical study in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top